InvestSMART

ORDINARY FULLY PAID (ASX: OPT) - Announcements

DELISTED - Current share price for OPT : $0.013

ASX company news and announcements for ORDINARY FULLY PAID (OPT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ORDINARY FULLY PAID (OPT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ORDINARY FULLY PAID (OPT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ORDINARY FULLY PAID (OPT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Opthea Presentation for EURETINA Congress 6 Sep 2019 9:02AM $3.740 $0.013 fallen by 99.65%
$18 Opthea Presents Positive Phase 2b Data at EURETINA Congress 6 Sep 2019 8:59AM $3.740 $0.013 fallen by 99.65%
$18 Opthea Ph2b of OPT-302 in wAMD to be Presented at EURETINA 4 Sep 2019 9:09AM $3.820 $0.013 fallen by 99.66%
$18 Change in substantial holding 29 Aug 2019 1:36PM $3.170 $0.013 fallen by 99.59%
$18 Change in substantial holding 27 Aug 2019 5:16PM $2.700 $0.013 fallen by 99.52%
$18 Change in substantial holding 19 Aug 2019 9:04AM $2.550 $0.013 fallen by 99.49%
$18 Change in substantial holding 15 Aug 2019 4:58PM $2.630 $0.013 fallen by 99.51%
$18 Becoming a substantial holder 14 Aug 2019 7:03PM $2.600 $0.013 fallen by 99.50%
$18 Change in substantial holding 14 Aug 2019 2:07PM $2.650 $0.013 fallen by 99.51%
$18 Appendix 3B 14 Aug 2019 9:03AM $2.600 $0.013 fallen by 99.50%
$18 Preliminary Final Report 9 Aug 2019 8:33AM $2.260 $0.013 fallen by 99.42%
$18 Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 7 Aug 2019 8:15AM $0.865 $0.013 fallen by 98.50%
$18 Opthea to Host Investor Teleconference 5 Aug 2019 4:28PM $0.865 $0.013 fallen by 98.50%
$18 Trading Halt 5 Aug 2019 8:55AM $0.865 $0.013 fallen by 98.50%
$18 Opthea European Patent Application to be Granted 30 Jul 2019 8:29AM $0.820 $0.013 fallen by 98.41%
$18 Opthea Provides Timing Update on OPT-302 Clinical Trials 22 Jul 2019 8:58AM $0.800 $0.013 fallen by 98.38%
$18 Change in substantial holding 4 Jun 2019 5:02PM $0.635 $0.013 fallen by 97.95%
$18 Opthea Completes Final Patient Visit in Phase 2b wAMD Trial 15 May 2019 8:24AM $0.680 $0.013 fallen by 98.09%
$18 Appendix 3B 12 Apr 2019 9:09AM $0.670 $0.013 fallen by 98.06%
$18 Change of Director's Interest Notice - MB 5 Apr 2019 8:56AM $0.730 $0.013 fallen by 98.22%
$18 Change of Director's Interest Notice - MS 19 Mar 2019 8:49AM $0.750 $0.013 fallen by 98.27%
$18 Change of Director's Interest Notice - GK 19 Mar 2019 8:45AM $0.750 $0.013 fallen by 98.27%
$18 Change of Director's Interest Notice - MB 19 Mar 2019 8:44AM $0.750 $0.013 fallen by 98.27%
$18 Appendix 3B 19 Mar 2019 8:40AM $0.750 $0.013 fallen by 98.27%
$18 Opthea Added to the S&P/ASX All Ordinaries Index 18 Mar 2019 8:26AM $0.755 $0.013 fallen by 98.28%

576 - 600 of 733 results

Page 24 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.